These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 1358974

  • 21. Amount of interleukin 12 available at the tumor site is critical for tumor regression.
    Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C, Stoppacciaro A.
    Cancer Res; 1996 Jun 01; 56(11):2531-4. PubMed ID: 8653692
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
    Hwang KS, Cho WK, Yoo J, Seong YR, Kim BK, Kim S, Im DS.
    Cancer Gene Ther; 2004 Jun 01; 11(6):397-407. PubMed ID: 15044962
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y, McGowan P, Hellström I, Hellström KE, Chen L.
    J Immunol; 1994 Jul 01; 153(1):421-8. PubMed ID: 7515929
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
    Tanaka M, Saijo Y, Sato G, Suzuki T, Tazawa R, Satoh K, Nukiwa T.
    Cancer Gene Ther; 2000 Nov 01; 7(11):1481-90. PubMed ID: 11129290
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Enhanced cell-mediated cytotoxicity by interferon-gamma and interleukin-2 against syngeneic murine mammary adenocarcinoma.
    Nakajima I, Chu TM.
    Mol Biother; 1992 Mar 01; 4(1):47-52. PubMed ID: 1627274
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.
    Adris S, Chuluyan E, Bravo A, Berenstein M, Klein S, Jasnis M, Carbone C, Chernajovsky Y, Podhajcer OL.
    Cancer Res; 2000 Dec 01; 60(23):6696-703. PubMed ID: 11118055
    [Abstract] [Full Text] [Related]

  • 34. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M, Hara I, Furukawa J, Oniki S, Nagai H, Miyake H, Fujisawa M.
    J Urol; 2007 Oct 01; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [Abstract] [Full Text] [Related]

  • 35. Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo.
    Chen W, Schweins E, Chen X, Finn OJ, Cheever MA.
    J Immunol; 1994 Oct 15; 153(8):3630-8. PubMed ID: 7930583
    [Abstract] [Full Text] [Related]

  • 36. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O, Schulze-Garg C, Warnecke G, Gugel R, Löhler J, Deppert W.
    J Virol; 2001 Nov 15; 75(22):10593-602. PubMed ID: 11602701
    [Abstract] [Full Text] [Related]

  • 37. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T, Harada M, Tamada K, Abe K, Nomoto K.
    Anticancer Res; 1997 Nov 15; 17(6D):4259-68. PubMed ID: 9494518
    [Abstract] [Full Text] [Related]

  • 38. Tumor secreting high levels of IL-15 induces specific immunity to low immunogenic colon adenocarcinoma via CD8+ T cells.
    Araki A, Hazama S, Yoshimura K, Yoshino S, Iizuka N, Oka M.
    Int J Mol Med; 2004 Oct 15; 14(4):571-6. PubMed ID: 15375583
    [Abstract] [Full Text] [Related]

  • 39. Role of host antigen receptor-bearing and antigen receptor-negative cells in immune response to rat adenocarcinoma 13762.
    Frey AB.
    J Immunol; 1996 May 15; 156(10):3841-9. PubMed ID: 8621922
    [Abstract] [Full Text] [Related]

  • 40. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
    Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS.
    Int Immunol; 2009 Jun 15; 21(6):655-65. PubMed ID: 19395374
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.